FDA Adverse Event Injury Summary report: N

PFC SIGMARP CV TB/IN S4 15.0

MDR report key: 5575888 · Received April 14, 2016

Report

Report Number
1818910-2016-17326
Event Type
Injury
Date Received
April 14, 2016
Date of Event
April 12, 2016
Report Date
April 12, 2016
Manufacturer
DEPUY RAYHNAM ¿ 1219655
Product Code
NJL
PMA / PMN Number
PP830055
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NC, US
Reporter Occupation
HEALTH PROFESSIONAL

Narratives

Additional Manufacturer Narrative · 1

NO DEVICE ASSOCIATED WITH THIS REPORT WAS RECEIVED FOR EXAMINATION. A COMPLAINT DATABASE SEARCH ON THE PROVIDED PFC SIGMARP CV TB/IN S4 15.0 (PRODUCT CODE 962043, LOT NUMBER 64960A) FOUND AN ADDITIONAL REPORT AND A DHR REVIEW WAS CONDUCTED. REVIEW OF THE DEVICE HISTORY RECORDS DID NOT REVEAL ANY RELATED MANUFACTURING DEVIATIONS OR ANOMALIES ON THE PROVIDED PRODUCT AND LOT COMBINATION. BASED ON PREVIOUS INVESTIGATIONS THIS COMPLICATION OF JOINT REPLACEMENT IS UNLIKELY TO HAVE BEEN THE RESULT OF A DEVICE FAILING TO MEET REQUIRED SPECIFICATIONS. THE INFORMATION RECEIVED WILL BE RETAINED FOR POTENTIAL SERIES INVESTIGATIONS IF TRIGGERED BY TREND ANALYSIS, POST MARKET SURVEILLANCE, OR OTHER EVENTS WITHIN THE QUALITY SYSTEM. CORRECTIVE ACTION WAS NOT INDICATED. DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE ADDITIONAL INFORMATION BE RECEIVED, THE INFORMATION WILL BE REVIEWED AND THE INVESTIGATION WILL BE RE-OPENED AS NECESSARY.

Additional Manufacturer Narrative · 1

THIS COMPLAINT IS STILL UNDER INVESTIGATION. DEPUY WILL NOTIFY THE FDA OF THE RESULTS OF THIS INVESTIGATION ONCE IT HAS BEEN COMPLETED. (B)(4). IF INFORMATION IS OBTAINED THAT WAS NOT AVAILABLE FOR THE INITIAL MEDWATCH, A FOLLOW-UP MEDWATCH WILL BE FILED AS APPROPRIATE.

Description of Event or Problem · 1

THE PATIENT WAS REVISED TO ADDRESS SPINOUT AND DELAMINATION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
234341 PFC SIGMARP CV TB/IN S4 15.0 KNEE TIBIAL BEARING/INSERT NJL DEPUY RAYHNAM ¿ 1219655 64960A

Patients

Seq Age Sex Outcome Treatment
1 74 YR Required Intervention